How Forma is working to show the sickle cell community it’s in for the long haul

As early clinical evidence for its sickle cell disease candidate grows, Forma is prioritizing building relationships with the patient community, with a focus on long-term policy goals and COVID-19 safety protections.

Forma Therapeutics Inc. (NASDAQ:FMTX) CEO Frank Lee said it’s crucial for companies to prove that their commitment to patient engagement goes beyond clinical trial recruitment and drug sales. “We’re a relative newcomer to the space. Building relationships takes many years of being there for the community,” said Lee...